Delta agent (b) was serially passaged to a second and third hepatitis B surface antigen (HBsAg) carrier chimpanzee, using as inoculum the peak delta antigen (bAg) serum of an animal previously infected with human serum. The characteristics of serially transmitted bAg were similar to those described in firstpassage animals. It was consistently detected before the development of anti-8, in association with a 35-to 37-nm subpopulation of HBsAg particles and a unique low-molecular-weight (5.5 x 105) RNA. RNase susceptibility of the delta-associated RNA and release of bAg activity upon treatment of delta-associated particles with detergent revealed that this particle is organized into a virion-like form with the RNA and bAg as internal components within a coat of HBsAg. Surface determinants of the delta-associated particle other than HBsAg were not detected by radioimmunoprecipitation experiments, using sera of humans and chimpanzees convalescent from delta hepatitis. The HBsAg-associated particle is the "candidate agent" of delta hepatitis.
Delta antigen (bAg) was first detected by immunofluorescence in hepatocyte nuclei of patients chronically infected with hepatitis B virus (HBV) (2, 9, 14) . The prevalence of antibody to bAg (anti-8) in human populations and transmission experiments in chimpanzees indicated that bAg represents a marker of a transmissible and pathogenic agent (delta agent; b) that requires helper functions of HBV for its expression (7, 8, 10, 13) . In chimpanzees experimentally infected with human serum, a transient delta antigenemia was observed before onset of hepatitis and development of anti-8: its detection required addition of 0.3% Nonidet P-40 (NP-40) and was temporally related to the development of bAg in the hepatocyte nuclei (10) .
bAg copurified with 35-to 37-nm particles which contained hepatitis B surface antigen (HBsAg) as well as a small RNA molecule (5.5 x 105 molecular weight) (12) . These particles had a buoyant density of 1.25 g/cm3 in CsCl and a sedimentation coefficient intermediate between that of the 22-nm HBsAg forms and the hepatitis B virion (Dane particle) (12) . A similar association of serum bAg with HBsAg and RNA was observed in a human HBV carrier with acute 8 infection (1) . The exact association of delta-associated RNA (DAR), bAg, and the 36-nm HBsAg particle, however, remained unclear. We report here studies on the organization and immunological properties of 8-associated particles purified from plasma of an experimentally infected chimpanzee. DAR and bAg represent internal components of the 36-nm particle (b particle) which are coated by HBsAg derived from the "helper" HBV infecting the host.
MATERIALS AND METHODS
Source of bAg. The animals inoculated in this study were chimpanzees 57 and 814; they were asymptomatic chronic carriers of HBsAg without serological evidence of prior exposure to 8 agent. Both animals had serum hepatitis B antigen (HBeAg) and DNA polymerase activity and intrahepatic hepatitis B core antigen (HBcAg).
The serum containing the peak bAg activity from chimpanzee 800 (1 ml, undiluted) was used as inoculum for the second passage of 8 agent to chronic HBsAg (adw) carrier chimpanzee 57. This animal developed intrahepatic bAg 2 weeks postinoculation and hepatitis at week 4. bAg appeared in the serum at week 2, rose to a peak level at week 4, and declined to unmeasurable levels at week 6. Hepatitis resolved and anti-8 seroconversion occurred at week 6 postinoculation. The serum containing peak bAg activity from chimpanzee 57 (1 ml, undiluted) was used as inoculum for a third passage of 8 to chronic HBsAg carrier chimpanzee 814. bAg appeared in liver at 2 weeks post-inoculation and in serum at week 3, rose to peak levels at week 4, and declined to undetectable levels with anti-b seroconversion at week 6. In both animals delta infection resulted in suppression of HBV replication; HBcAg disappeared from hepatocyte nuclei and DNA polymerase activity was no longer detectable in serum. Serum bAg had characteristics identical to those previously reported in the first-passage chimpanzees; it was detected only after detergent (NP-40) treatment of serum, copurified with a 35-to 37-nm subpopulation of HBsAg particles, and was associated with a small RNA molecule (5.5 x 105 molecular weight). Further experiments were conducted with 8-associated particles obtained from serum of chimpanzee 814 when bAg was at its highest titer.
Assays. HBsAg, anti-HBs, anti-HBc, HBeAg, and antiHBe activities were determined by commercial radioimmunoassays (Ausria II, Ausab, Corab, and Abbott-HBe; Abbott Laboratories); dilutions were made in Pi-NaCl (0.85% NaCl, 0.01 M phosphate buffer, pH 7.4). HBcAg, bAg, and anti-b were detected by microtiter solid-phase radioimmunoassays, as described previously (3, 8, 10) . Pellets and fractions of gradients were tested for bAg activity after dilution in Pi-NaCl containing 0.3% NP-40. HBsAgspecific DNA polymerase activity was measured as previously reported (4).
Preparations of 8-associated particles. Delta-associated particles were isolated from plasma by isopycnic banding in CsCl and rate zonal sedimentation in sucrose as previously described (1, 12) . Briefly, two 5-ml samples of bAg-positive plasma (recalcified and clarified at 2,000 rpm for 10 min) were pelleted through a cushion of 20% (wt/wt) sucrose-P,-NaCl and centrifuged for 5 h at 193,000 x g and 4°C. The resulting pellets were resuspended to a combined volume of 0.5 ml with Pi-NaCl, layered on top of an 11.0-ml discontinuous gradient (1.2 to 1.5 g/cm3) of CsCI in Pi-NaCl, and centrifuged for 24 h at 108,000 x g and 4°C; fractions were collected by bottom puncture and assayed for HBsAg and bAg. The bAg peak fractions (1.245 g/cm3 in CsCl) were pooled, diluted in P1-NaCl, and centrifuged for 5 h at 193,000
x g and 4°C. The pellet was resuspended in 1 ml of Pi-NaCl (P2) and used as a source of 8-associated particles.
lodination of 8-associated particles. Delta particle preparations (P2) were iodinated by the chloramine-T procedure (16); 400 ,uCi of Na125I (New England Nuclear Corp.), 2 nmol of NaI (Fisher Scientific Co.), and 20 pug of chloramine-T (Eastman Kodak Co.) were added to 50 RI of P2 samples. The gel was stained with 1 ,ug of ethidium bromide per ml and visualized at 254 nm. Samples of the dried precipitates were dissolved in 0.2 ml of 0.15 M NaCI-0.01 M Trishydrochloride, pH 7.4; solutions minus Tris-hydrochloride had been treated with diethyl pyrocarbonate and autoclaved. Pancreatic RNase (heated for 10 min at 90°C before use; Worthington Diagnostics) was added at various concentrations (0.1 to 10 ,ug/ml). After incubation for 0.5 h at 37°C, the reaction was stopped with lysing solution, preparations were extracted with phenol chloroform, and the aqueous phase was ethanol precipitated. Precipitates were electrophoresed and stained with ethidium bromide as described above.
Electron microscopy. A Hitachi HU-11E electron micro- scope was used to examine preparations of b-associated particles after negative staining with 1% phosphotungstic acid.
RESULTS RIP of purified 8-associated particles. Samples of iodinated 8-associated particles were purified by rate zonal sedimentation on a linear sucrose gradient. Three peaks of radioactivity were obtained ( Fig. 1) : one was immunoprecipitated by guinea pig anti-HBs and, after 0.3% NP-40 treatment, also by anti-8; the other two peaks were only precipitated by antiHBs. No RIP was obtained with anti-HBc serum (serum 4, 1/50 dilution; Table 1 ) or with guinea pig preimmunization serum, used as controls. The radioactivity of the fractions corresponding to b-associated particles was 90 to 95% precipitable by 10% trichloroacetic acid. Since iodinated particles were precipitated by anti-b-positive serum only after treatment with 0.3% NP-40 and no significant RIP was obtained without detergent, the preparation was considered to represent intact particles, separated from the bulk of HBsAg.
Intact and disrupted 125I-labeled 8-associated particles (5 ,ul) were used for RIP assays with sera listed in Table 1 . Antib-positive sera from humans and chronic HBsAg carrier chimpanzees, convalescent from acute 8 hepatitis, failed to precipitate intact particles, whereas significant RIP was obtained with the anti-HBs-positive serum and after disruption of particles with 0.3% NP-40. HBV-susceptible chimpanzee 32 developed an acute type B hepatitis and recovered with seroconversion to anti-8 and subsequently anti-HBs (10) . An anti-b-positive serum from chimpanzee 32, obtained before anti-HBs seroconversion, did not precipitate intact particles, whereas a significant RIP was achieved with another serum, obtained from the same animal, after appearance of anti-HBs (Table 1) .
Composition of the purified 8-associated particle. Samples of iodinated and purified b-associated particles (0.25 ml of VOL. 43, 1984 on October 28, 2017 by guest http://iai.asm.org/ Downloaded from fraction 3, Fig. 1 ) were treated with detergent (0.3% NP-40) and centrifuged in a CsCl gradient. SAg activity banded at a buoyant density of 1.283 g/cm3, well separated from HBsAg ( Fig. 2A) , and no HBcAg or endogenous DNA polymerase activities were detected in the preparation. The density of SAg released from the particle was identical to that of antigen extracted from human liver (14) . Double-antibody RIP analysis, however, revealed that 50 and 75% of radioactivity was precipitated by anti-HBs and anti-8 sera, respectively, indicating that at this stage of purification BAg remains associated to some extent with HBsAg-reactive material.
DAR. The S-particle preparation (P2, 0.5 ml) was sedimented as described for 125I-labeled particles; SAg-positive (10) .The mean anti-HBc titer in all of these sera was 10-4 (range, 10-3 to 10-6). of CsCl in Pi-NaCl for 24 h at 108,000 x g and 4°C. Fractions (0.5 ml)
were collected by bottom puncture and directly counted (10 ,ul; 0); dilutions were made in Pi-NaCl plus 0.5% bovine serum albumin and 0.1% 2-mercaptoethanol. HBsAg (1/20 dilution, El) and SAg (1/5 dilution; ) were assayed directly on antibody-coated solid-phase plates or beads used in radioimmunoassays. CsCl density was determined by refractometry (A). (B) Purified unlabeled 8-associated particles (0.5 ml) treated with NP-40 were banded on a discontinuous CsCl gradient as described for 125I-labeled particles. Fractions (0.5 ml) collected by top aspiration were assayed at 1/5 dilution for bAg (0), HBcAg (0), or HBsAg (A) by radioimmunoassay. CsCl density was determined by refractometry (M).
fractions were pelleted and resuspended to 0.25 ml in PiNaCl. Spherical 35-to 37-nm particles were observed by electron microscopy. Purified 8-associated particles were treated with detergent and banded in a discontinuous CsCl gradient as described above for labeled particles; vanidyl ribonucleoside complex (Bethesda Research Laboratories Inc.) was added to inhibit RNase (10 mM final concentration). Fractions (0.5 ml) were collected by top aspiration and assayed for SAg and HBsAg by radioimmunoassays (Fig.  2B) . The peak SAg activity contained a small amount of HBsAg, and no "corelike" structures were observed by electron microscopy.
Fractions from three regions of the gradient were pooled: (i) the peak bAg region (fractions 6 detected by electrophoresis in the initial preparation and in lower quantity after 48 h, but was not detectable at 72 h. These data are consistent with the gradual opening of the bassociated particles under these storage conditions and the accessibility of DAR to environmental RNase. To analyze the integrity of the serum-derived particles, b-associated particles were subjected to a graded series of RNase conditions. An equivalent amount of DAR was observed with each concentration of RNase (Fig. 6) , indicating that DAR of the serum-derived particle is not accessible to RNase. DAR was not recovered after RNase treatment of particles disrupted by detergent.
DISCUSSION
The 8 agent was serially passaged in a second and third HBsAg carrier chimpanzee, using as inoculum the serum obtained at the peak of bAg from another animal infected with human serum. bAg was found in the blood of these animals during a relatively narrow time span of about a month before the appearance of anti-8 and was associated with 35-to 37-nm particles of HBsAg and a low-molecularweight (5.5 x 105) RNA.
The titers of bAg and 8-associated RNA (DAR as detected by ethidium bromide fluorescence) were positively correlated and both quickly declined with the appearance of anti-8 in the serum. Surface determinants of the b-associated particle other than HBsAg were not detected by RIP experiments, using sera of humans and chimpanzees convalescent from 8 hepatitis. Since anti-b sera do not precipitate intact particles, the rapid clearance of bAg and DAR from serum remains unexplained, and mechanisms other than immune clearance mediated by anti-8 must be involved in the disappearance of bAg from serum. Intranuclear IgG has been reported in the liver of experimentally infected chimpanzees only after the appearance of anti-b in the serum (11) . In view of this, anti-b antibody may play a major role in inhibiting or possibly blocking the release of bAg and DAR from infected hepatocytes.
bAg and DAR were shown to be internal components of the 8-associated particle as their detection requires disrup-80; the top of the gradient, and (iii) the bottom of the gradient (fractions 1 to 5). The pellet from the gradient was resuspended to 0.25 ml of 0.02 M NaCl and. 0.01 M sodium EDTA-0.05 M HEPES, pH 7.4. Each fraction was dialyzed for 18 h at 4°C in a large volume of the same buffer. The three pools and the resuspended pellet were then analyzed for DAR by electrophoresis (Fig. 3) . DAR was not detected in the gradient fractions but was recovered in the resuspended pellet (1.5 g/cm in CsCI). These data indicate that detergent treatment of the particle resulted in release of the DAR.
To evaluate the stability of this particle, purified particles from a sucrose gradient were assayed for 8 activity by RIP after 12, 24, 48, and 72 h of storage in 30% sucrose-Pi-NaCl at 4°C. Within 48 h bAg activity increased to the value of the NP-40-treated control preparation. In the same time period, however, the control preparation showed a decrease which stabilized at approximaely 50% of the initial value (Fig. 4) . At each time point the preparation was examined by electron microscopy; particles were randomly photographed and the percentage of empty particles was determined. At 12 h, 10% of the particles appeared empty (Fig. 5A) , whereas the percentage rose to 75% after 72 h (Fig. SB) tion of the particles. Free DAR was recovered in the pellet of a CsCl gradient (>1.50 g/cm3) after detergent treatment of the particles; in the same preparation BAg banded with a buoyant density (1.28 g/cm3 in CsCI) identical to that of BAg extracted from liver (14) . At this stage of purification, however, a discrete amount of HBsAg was still present in the MAg preparation, and further purification attempts were unsuccessful due to the loss of antigenic activity by aggregation. As in previous studies (1, 12) , particulate forms were not seen by electron microscopy, suggesting that MAg and DAR are not organized in an internal corelike structure. The 5-associated particle coexists with acute 8 infection in humans and chimpanzees, and 8 infectivity is presumably maintained by the integrity of this particle. Furthermore, the serum-derived particle is organized in such a manner that the DAR is protected from endogenous RNase. The consistent association of DAR with MAg as internal components of the particle raises the possibility that DAR represents the genome of 8 and SAg represents a nucleoprotein. There is, however, no evidence as yet that the DAR codes for the only established 8 gene product, the SAg. There is sufficient evidence to indicate that 8 is not a variant of HBV but, rather, a unique non-A, non-B agent which requires the helper function of HBV for its expression and replication. The 36-nm particle which contains BAg and DAR has many of the structural characteristics of a virion and could well be considered the "candidate agent" of 8 hepatitis.
FIG. 6 . Integrity of serum-derived S-associated particles. The serum pellet (P1) obtained, as described above, from 2 ml of bAg-0.1 ,ug/ml) to three of them. After incubation at 37°C, the mixtures positive serum was resuspended to 0.25 ml of Pi-NaCl and mixed were analyzed by electrophoresis for DAR as described in the text. 
